These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23772153)

  • 1. Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes.
    Oh TJ; Jung HS; Bae JH; Kim YG; Park KS; Cho YM; Park KS; Kim SY
    J Korean Med Sci; 2013 Jun; 28(6):881-7. PubMed ID: 23772153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.
    Signorovitch JE; Wu EQ; Swallow E; Kantor E; Fan L; Gruenberger JB
    Clin Drug Investig; 2011; 31(9):665-74. PubMed ID: 21819162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.
    Rizzo MR; Barbieri M; Marfella R; Paolisso G
    Diabetes Care; 2012 Oct; 35(10):2076-82. PubMed ID: 22688551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
    Mikhail N
    Vasc Health Risk Manag; 2008; 4(6):1221-7. PubMed ID: 19337535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
    Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch CL
    Cochrane Database Syst Rev; 2008 Apr; 2008(2):CD006739. PubMed ID: 18425967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects.
    Elhini SH; Hussien AK; Omran AAE; Elsayed AA; Saeed H
    Clin Exp Pharmacol Physiol; 2021 Dec; 48(12):1589-1602. PubMed ID: 34333803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New treatments for diabetes.
    Bloomgarden ZT; Inzucchi SE
    N Engl J Med; 2007 May; 356(21):2219-20; author reply 2222-3. PubMed ID: 17522409
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
    Ahrén B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):487-98. PubMed ID: 19748066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.
    Barbieri M; Rizzo MR; Marfella R; Boccardi V; Esposito A; Pansini A; Paolisso G
    Atherosclerosis; 2013 Apr; 227(2):349-54. PubMed ID: 23375680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
    Foley JE; Bhosekar V; Kawamori R
    Vasc Health Risk Manag; 2016; 12():9-12. PubMed ID: 26855580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
    Chen YW; Wang JS; Sheu WH; Lin SY; Lee IT; Song YM; Fu CP; Lee CL
    PLoS One; 2017; 12(2):e0171753. PubMed ID: 28182722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.
    Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch C
    Vasc Health Risk Manag; 2008; 4(4):753-68. PubMed ID: 19065993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
    Kleefstra N; van Hateren KJ; Houweling ST; Verhoeven S; Kooy A; Goudswaard AN; Bilo HJ
    Ned Tijdschr Geneeskd; 2010; 154():A886. PubMed ID: 20298625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DPP-4 inhibitor treatment: β-cell response but not HbA
    Kozlovski P; Bhosekar V; Foley JE
    Vasc Health Risk Manag; 2017; 13():123-126. PubMed ID: 28408838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difference between observed and predicted glycated hemoglobin at baseline and treatment response to vildagliptin-based dual oral therapy in patients with type 2 diabetes.
    Wang JS; Hung YJ; Lu YC; Tsai CL; Yang WS; Lee TI; Hsiao YC; Sheu WH
    Diabetes Res Clin Pract; 2018 Apr; 138():119-127. PubMed ID: 29444447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis.
    Park SH; Nam JY; Han E; Lee YH; Lee BW; Kim BS; Cha BS; Kim CS; Kang ES
    Medicine (Baltimore); 2016 Aug; 95(32):e4543. PubMed ID: 27512877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
    Ahrén B
    Vasc Health Risk Manag; 2008; 4(2):383-94. PubMed ID: 18561513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DPP-4 inhibitors in clinical practice.
    Palalau AI; Tahrani AA; Piya MK; Barnett AH
    Postgrad Med; 2009 Nov; 121(6):70-100. PubMed ID: 19940419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.